Bevacimab 100 mg/4 ml (IV Infusion)
100 mg vial: ৳ 16,100.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Bevacizumab |
| Company | Healthcare pharmaceuticals ltd |
| Also available as |
Indications
- Treatment of metastatic colorectal cancer
- Treatment of non-squamous non-small cell lung cancer
- Treatment of glioblastoma
- Treatment of metastatic renal cell carcinoma
- Treatment of cervical cancer
- Treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
- Limitation of use: not indicated for adjuvant treatment of colon cancer
Pharmacology
- Recombinant humanized monoclonal IgG1 antibody
- Binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF)
- Approximate molecular weight of 149 kD
- Produced in a mammalian cell (Chinese Hamster Ovary) expression system
- Clear to slightly opalescent, colorless to pale brown, sterile, pH 6.2 solution
Dosage
- Recommended doses for different types of cancer
- Dosing intervals and combinations with other chemotherapy drugs
Administration
- Not to be administered as an IV push or bolus
- Initiation after major surgery
- Preparation for administration
- Infusion duration for first and subsequent infusions
- Dilution instructions and product characteristics
Interaction
- No significant effect on the pharmacokinetics of irinotecan or its active metabolite SN38
Contraindications
- No contraindications listed in the manufacturer's labeling
Side Effects
- Most common adverse reactions
- Incidence >10% and at least twice the control arm rate
Pregnancy & Lactation
- Potential fetal harm based on findings from animal studies and the drug's mechanism of action
- Adverse reactions in breastfed infants from Bevacizumab
- Recommendation against breastfeeding during treatment
Precautions & Warnings
- Discontinuation criteria for perforation or fistula, arterial and venous thromboembolic events, hypertension, posterior reversible encephalopathy syndrome, proteinuria, and infusion reactions
- Advising females of potential risk to a fetus and the need for effective contraception
- Advising females of the potential risk of ovarian failure
Use in Special Populations
- Safety, effectiveness, pharmacokinetic profile in pediatric patients not established
- Cases of non-mandibular osteonecrosis in patients under 18 years
- Insufficient information to determine safety and efficacy in children with glioblastoma
- Physeal dysplasia observed in juvenile cynomolgus monkeys
- Increased incidence of severe adverse events in geriatric patients
Overdose Effects
- Highest tested dose in humans associated with headache
Therapeutic Class
- Targeted Cancer Therapy
Storage Conditions
- Refrigeration at 2-8°C
- Light sensitivity precautions
- Not to be frozen
- Keep out of reach of children